World Osteoarthritis Therapeutics Market Outlook to 2024 - Viscosupplementation Agents to Register the Highest Growth

10/22/2019, 3:11 PM (Source: GlobeNewswire)

Dublin, Oct. 22, 2019 (GLOBE NEWSWIRE) -- The "Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) - Global Forecast to 2024" report has been added to's offering.

The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8 billion in 2019, at a CAGR of 8.1%.

Growth in this industry is driven by the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. On the other hand, the availability of alternative non-drug pain management therapies is a major market challenge.

Key players in the osteoarthritis therapeutics market include Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline plc (UK), Bayer AG (Germany), Abbott (US), Pfizer (US), Eli Lilly (US), Anika Therapeutics (US), and Flexion Therapeutics (US).

Knee osteoarthritis segment to witness the highest growth during the forecast period

Based on anatomy, the osteoarthritis therapeutics market is segmented into knee, hip, hand, and small-joint. The knee osteoarthritis segment is projected to grow at the highest CAGR during the forecast period. A large number of patients suffering from knee osteoarthritis is the major factor supporting the growth of this segment.

Viscosupplementation agents segment to register the highest growth in the osteoarthritis therapeutics market during the forecast period

Based on drug type, the osteoarthritis therapeutics market is segmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is sub-segmented into duloxetine and acetaminophen, while the NSAIDs segment is sub-segmented into naproxen, aspirin, diclofenac, ibuprofen, and other molecules. The viscosupplementation agents segment is projected to witness the highest growth in the osteoarthritis therapeutics market during the forecast period. The rising incidence of knee osteoarthritis is one of the major factors supporting the growth of this segment.

Asia Pacific is estimated to register the highest CAGR during the forecast period

In this report, the osteoarthritis therapeutics market is segmented into four major regional segments, namely, Europe, North America, Asia Pacific, and the Rest of the World (RoW). The market in Asia-Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is driven primarily by the rising incidence and prevalence of osteoarthritis, increasing geriatric and obese populations, and healthcare infrastructure improvements in several APAC countries.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Osteoarthritis Therapeutics Market Overview
4.2 Europe: Market Share, By Anatomy (2018)
4.3 Geographical Snapshot of the Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers Rapid Growth in the Geriatric and Obese Populations and the Associated Increase in the Prevalence of Osteoarthritis Increasing Incidence of Sports Injuries
5.2.2 Restraints Risk of Adverse Cardiovascular Events Associated With the Use of Nsaids in Osteoarthritis Treatment
5.2.3 Opportunities Emerging Markets Strategic Collaborations Focused on New Product Development
5.2.4 Challenges Availability of Alternative Non-Drug Pain Management Therapies

6 Osteoarthritis Therapeutics Market, By Anatomy
6.1 Introduction
6.2 Knee Osteoarthritis
6.2.1 Rising Obese and Geriatric Populations to Increase the Prevalence of Knee Osteoarthritis
6.3 Hip Osteoarthritis
6.3.1 Similar to Knee Osteoarthritis, Hip Osteoarthritis is More Common in the Geriatric and Obese Populations
6.4 Hand Osteoarthritis
6.4.1 Rising Prevalence of Shoulder Osteoarthritis to Drive Market Growth
6.5 Small-Joint Osteoarthritis
6.5.1 Rising Number of Ankle-Related Sports Injuries to Increase the Prevalence of Ankle Osteoarthritis

7 Osteoarthritis Therapeutics Market, By Drug Type
7.1 Introduction
7.2 Viscosupplementation Agents
7.2.1 Viscosupplementation Agents Dominated the Market in 2018
7.3 Nonsteroidal Anti-Inflammatory Drugs
7.3.1 Nsaids Can Relieve Pain and Inflammation Without the Various Potential Adverse Effects Associated With Corticosteroids Ibuprofen Diclofenac Aspirin Naproxen Other Molecules
7.4 Analgesics
7.4.1 Acetaminophen
7.4.2 Duloxetine
7.5 Corticosteroids

8 Osteoarthritis Therapeutics Market, By Route of Administration
8.1 Introduction
8.2 Oral Route
8.3 Parenteral Route
8.4 Topical Route

9 Osteoarthritis Therapeutics Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Online Pharmacies
9.4 Retail Pharmacies

10 Osteoarthritis Therapeutics Market, By Purchasing Pattern
10.1 Introduction
10.2 Prescription Drugs
10.2.1 Prescription Drugs to Account for A Larger Share of the Market
10.3 Over-The-Counter Drugs
10.3.1 Ease of Purchase and Administration Resulting in A Rising Demand for Otc Drugs

11 Osteoarthritis Therapeutics Market, By Region
11.1 Introduction
11.2 Europe
11.2.1 Italy
11.2.2 Germany
11.2.3 Spain
11.2.4 France
11.2.5 UK
11.2.6 Rest of Europe
11.3 North America
11.3.1 US
11.3.2 Canada
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia Pacific
11.5 Rest of the World

12 Competitive Landscape
12.1 Overview
12.2 Market Ranking Analysis, 2018
12.3 Competitive Scenario
12.3.1 Product Launches and Approvals, 2016-2019
12.3.2 Collaborations, 2016-2019
12.3.3 Expansions, 2016-2019
12.3.4 Acquisitions, 2016-2019
12.3.5 Other Developments
12.4 Competitive Leadership Mapping
12.4.1 Vendor Inclusion Criteria
12.4.2 Visionary Leaders
12.4.3 Innovators
12.4.4 Dynamic Differentiators
12.4.5 Emerging Companies

13 Company Profiles
13.1 Sanofi
13.2 Horizon Therapeutics PLC
13.3 Johnson & Johnson
13.4 GlaxoSmithKline PLC
13.5 Bayer AG
13.6 Abbott
13.7 Pfizer, Inc.
13.8 Eli Lilly
13.9 Anika Therapeutics, Inc.
13.10 Novartis
13.11 Ferring Pharmaceuticals
13.12 Bioventus
13.13 Zimmer Biomet Holdings, Inc.
13.14 Fidia Farmaceutici S.P.A.
13.15 Flexion Therapeutics, Inc.

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.